Written by
Investing News Network: Software Company Strainprint Wants to Change the Limitations of Medical Cannabis Research
On August 30th, 2017 Strainprint was featured on the Investing News Network. Our President, Dave Berg spoke to the Investing News Network about Strainprint and how we’re working to change the limitations of Medical Cannabis Research.
Coinciding with the adult use legalization of cannabis across North America, an opioid epidemic has emerged. It is estimated that more than 130 people die each day due to opioid overdose in the United States alone, according to the U.S. Department of Health and Human Services (HHS). The organization reported that, in 2017, nearly 50,000 Americans died […]
Camphene, sometimes called comphene, is one of more than 200 terpenes discovered to date in hemp and cannabis. Terpenes are aromatic molecules once thought to convey only aroma and, from an evolutionary functional perspective, to protect a plant from pests and predators. In recent years, however, much clinical research, in addition to anecdotal evidence, has […]
Welcome to the Strainprint Community Understanding Terpenes Series. Before diving into the details behind beta-caryophyllene (BCP, caryophyllene, or β-caryophyllene), the molecule produced by cannabis known for its categorization as both a terpene and a cannabinoid that provides pain killing and anti-inflammatory benefits, it behooves readers to develop a solid understanding of terpenes as a category of wellness molecule. Patients […]